ArticleScientific reports2025
The risk of heart-specific death in breast cancer patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Blueprint for adapting the cardiac rehabilitation model for oncology patients with cardiovascular-kidney-metabolic syndrome.American journal of preventive cardiology · 2026Article
- Cardiovascular Disease in Males With Breast Cancer: A Population-Based Cohort Study.JACC. Advances · 2026Article
- Cardioprotection for radiation-induced heart disease in breast cancer patients.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
With the improvement of comprehensive anti-cancer treatment for breast cancer (BC), more and more BC survivors will die from non-cancer diseases, including cardiovascular disease dominated by heart disease (HD). Therefore, this study aimed to analyze the risk of heart-specific death (HSD) in patients with BC by using the Surveillance, Epidemiology, and End Results (SEER) database. The eligible patients diagnosed with BC between 2000 and 2019 were exported from the SEER database. The standard mortality ratios (SMR) were calculated to compare the difference in HSD between patients with BC and the general population. The Cox Proportional hazard model was used to estimate the risk factors for HSD in BC patients and the 95% confidence intervals (CI) were calculated. Overall, 655,552 eligible patients were included in our study, and 149,708 (22.8%) patients died. Among the deaths, 22,718 (15.2%) cases were attributed HD which was the second cause of death for BC patients. With the extension of follow-up (> 10 years), HD surpassed breast cancer as the leading cause of death for BC (22.3% vs. 20.2%). The SMR for HD was 8.14 (95%CI: 8.04-8.25) in the whole cohort. Multivariate analysis showed that race, age, marital status, median household income, grade, stage and subtype were independent risk factors for HSD in BC patients. The risk of HSD is significantly higher in BC patients than in the general population and closely related to demographic characteristics and tumor clinicopathological factors. Medical approaches are needed to reduce the risk of HD among patients with BC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.